PHAXIAM Therapeutics announces a reverse share split of its shares

News & events

Press release
PHAXIAM Therapeutics announces a reverse share split of its shares

Read more
Press release
PHAXIAM Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM

Read more
Communiqués
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics

Read more
Press release
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023

ERYTECH Pharma (Euronext Paris & Nasdaq: ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023

Read more
Press release
ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit

ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit

Read more
Press release
ERYTECH announces that the Commercial Court has rejected Akkadian’s request to postpone the vote on the merger with Pherecydes Pharma

ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma

Read more
Press release
ERYTECH Responds to Akkadian’s Disinformation

ERYTECH Responds to Akkadian’s Disinformation

Read more
Press release
ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes

ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes

Read more
Press release
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023

Read more
Press release
ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes

ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes

Read more

Contact
our team

Journalist, investor, healthcare professional, partner or candidate... if you have any questions about PHAXIAM, please do not hesitate to contact our teams.

Contact us